Last reviewed · How we verify
E coli H10407 and buffer — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
E coli H10407 and buffer (E coli H10407 and buffer) — Johns Hopkins Bloomberg School of Public Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| E coli H10407 and buffer TARGET | E coli H10407 and buffer | Johns Hopkins Bloomberg School of Public Health | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- E coli H10407 and buffer CI watch — RSS
- E coli H10407 and buffer CI watch — Atom
- E coli H10407 and buffer CI watch — JSON
- E coli H10407 and buffer alone — RSS
Cite this brief
Drug Landscape (2026). E coli H10407 and buffer — Competitive Intelligence Brief. https://druglandscape.com/ci/e-coli-h10407-and-buffer. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing